Press-release for stocks publishing date 2021 - 10

Prices are updated after-hours

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
Published: 2021-10-14 (Crawled : 21:00) - globenewswire.com
VRTX | $400.66 -1.05% -1.06% 810K

| 120.32% | O: 0.32% H: 0.37% C: -0.39%
SGEN | $228.74 0.1% 20M

| 34.4% | O: 0.24% H: 2.56% C: 1.25%
SNY | News | $46.66 -2.16% -2.21% 1.7M

| -4.07% | O: -0.35% H: 1.12% C: 0.89%
NRIX | $13.73 -2.83% -2.91% 520K

| -51.75% | O: 0.91% H: 1.23% C: 0.24%
financial results results

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer
Published: 2021-10-14 (Crawled : 18:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

| -3.34% | O: 1.2% H: 0.08% C: -0.43%
lung cancer cancer therapy

Tentarix Biotherapeutics Emerges with $50 Million Series A
Published: 2021-10-14 (Crawled : 14:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

| -3.34% | O: 1.2% H: 0.08% C: -0.43%
FATE | News | $4.3 -5.29% -5.58% 2M

| -92.85% | O: 1.41% H: 3.89% C: 2.48%
iot merge

| -3.34% | O: 1.2% H: 0.08% C: -0.43%
AGTC | News | $0.3936 1.23% 0.0%

| -85.64% | O: 0.36% H: 2.55% C: -0.73%

MAIA Biotechnology, Inc. Announces $6.2 Million Financing to Advance Targeted Immuno-Oncology Studies
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

| -3.34% | O: 1.2% H: 0.08% C: -0.43%
biotech technology iot

FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

| -3.34% | O: 1.2% H: 0.08% C: -0.43%
REGN | News | $906.55 -0.09% -0.08% 370K

| 65.69% | O: 1.07% H: 2.19% C: 0.47%
covid treatment fda casirivimab fda acceptance

CRISPR Therapeutics Announces Transition of Chief Financial Officer
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M